Table 1 Comparison of clinical characteristics between the relapsed group and the non-relapsed group

Age, years

62.7 ± 13.8

62.6 ± 7.4

0.985

Sex

 Male, n (%)

25(75.8)

12(66.7)

0.714

 Female, n (%)

8(24.2)

6(33.3)

BMI

22.2 ± 2.5

22.3 ± 2.1

0.831

Past history

 Diabetes, n (%)

7(21.2)

3(16.7)

0.983

 Smoke, n (%)

16(48.5)

9(50)

0.918

 Alcohol, n (%)

15(45.5%)

11(61.1)

0.285

Clinical symptoms

 Obstructive jaundice, n (%)

23(69.7)

11(61.1)

0.534

 Abdominal pain, n (%)

19(57.6)

8(44.4)

0.369

 Acute pancreatitis, n (%)

1(3.0)

2(11.1)

0.583

 Lose weight, n (%)

15(45.5)

8(44.4)

0.945

Laboratory tests

 IgG4, mg/dL

1190.0(556.5–2420.0)

588.0(319.8–964.8)

0.008

 TB, umol/L

71.2(30.8–166.3)

69.6(17.6–194.0)

0.921

 Cr, umol/L

63.3(54.7–73.5)

64.7(51.4–67.9)

0.775

 WBC, × 109/L

6.1(5.3–7.7)

5.2(4.6–6.7)

0.200

 LDH, U/L

155.9(128.3–187.0)

153.9(137.2–186.5)

0.937

Initial treatment

 Glucocorticoids alone, n (%)

13(41.9)

2(11.1)

–

 Glucocorticoids+Immunosuppressant, n (%)

7(22.6)

8(44.4)

–

 Glucocorticoids+Biliary drainage, n (%)

5(16.1)

0(0)

–

 Biliary drainage, n (%)

3(9.7)

1(5.6)

–

 Biliary drainage+ Immunosuppressant, n (%)

3(9.7)

4(22.2)

–

 Immunosuppressant, n (%)

2 (6.5)

3 (16.7)

–